Many patients feel overwhelmed when they first hear terms like LAMN, HAMN, or pseudomyxoma peritonei (PMP). A recent large study from MD Anderson Cancer Center brings much-needed clarity to how these tumors behave and what patients can expect. Below is a simple, easy-to-understand summary of the findings — designed for patients, caregivers, and anyone navigating this diagnosis.
What are LAMN and HAMN?
Appendiceal mucinous neoplasms are tumors that produce mucin — the jelly-like substance that can fill the appendix. There are two main grades:
- LAMN: low-grade, slower-growing
- HAMN: high-grade, the cells look more abnormal under a microscope
Both can sometimes leak mucin or tumor cells into the abdomen. When this happens, patients can develop pseudomyxoma peritonei (PMP), which often requires major surgery and heated chemotherapy (HIPEC).
1. HAMN Is More Likely to Spread in the Abdomen
One of the most important findings from the study is that HAMN is more likely than LAMN to spread outside the appendix.
- 69.7% of HAMN patients had disease in the abdomen
- 43.1% of LAMN patients did
HAMN also showed more high-grade spread — meaning the disease in the belly tended to be more aggressive.
2. When Tumors Stay Inside the Appendix, Surgery Works Very Well
There is very good news for patients with either LAMN or HAMN that is confined to the appendix:
- An appendectomy alone was almost always curative.
- Recurrence was extremely rare, even in patients with HAMN.
This means that HAMN does not act aggressively when it hasn’t spread.
3. If Mucin Spreads Into the Belly, the Type of Spread Matters Most
Not all abdominal spread is the same. The study broke it into three groups:
Acellular mucin (best case)
Mucin leaks out, but there are no tumor cells in it.
→ Very low risk of recurrence
Low-grade mucinous peritoneal disease (LGMCP)
Tumor cells are present, but they are low grade.
→ Moderate risk
High-grade mucinous peritoneal disease (HGMCP)
More aggressive tumor cells are found in the belly.
→ Highest risk of recurrence and lower survival
This means the grade of disease in the belly is more important than whether the primary tumor was LAMN or HAMN.
4. Overall Survival Was Similar for HAMN and LAMN
Despite HAMN being more likely to spread, the long-term outcomes for patients were similar:
- 5-year survival for LAMN: 93.4%
- 5-year survival for HAMN: 91.1%
Most patients, in both groups, lived many years after diagnosis — especially when treated early.
5. The Highest-Risk Patients: HAMN + High-Grade Peritoneal Disease
The group that did the worst overall were patients who had:
- HAMN and
- High-grade mucinous peritoneal disease (HGMCP)
These patients may need closer follow-up and more aggressive treatment.
6. Genetic Findings Provide More Clues
Researchers found:
- KRAS and GNAS mutations were common in both LAMN and HAMN
- TP53 mutations appeared only in HAMN, which may help explain why it behaves more aggressively
This information may guide future treatments and clinical trials.
What This Study Means for Patients
If your tumor was only in the appendix:
Your chance of recurrence is extremely low — even if you had HAMN.
If mucin leaked but had no tumor cells:
Your outlook is excellent.
If low-grade tumor cells were found in the belly:
There is some risk, but most patients still do very well.
If high-grade tumor cells were found in the belly:
You may need more intensive treatment and follow-up. This group deserves more research and support.
Why This Matters
Appendix cancer patients often struggle to find clear, trustworthy information. This study — the largest ever conducted on HAMN — brings hope and clarity:
- Most patients, even with HAMN, have excellent long-term survival
- Not all spread is dangerous
- The biology of the disease matters — and we’re learning more every year
Better research leads to better outcomes. And every patient deserves access to the full picture — in language that makes sense.
Full study can be found here: https://link.springer.com/article/10.1245/s10434-025-18672-0
Leave a Reply